Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12, 975-995
eCollection

Pooled Analysis of Tanezumab Efficacy and Safety With Subgroup Analyses of Phase III Clinical Trials in Patients With Osteoarthritis Pain of the Knee or Hip

Affiliations

Pooled Analysis of Tanezumab Efficacy and Safety With Subgroup Analyses of Phase III Clinical Trials in Patients With Osteoarthritis Pain of the Knee or Hip

Leslie Tive et al. J Pain Res.

Abstract

Purpose: A pooled analysis was conducted to evaluate tanezumab efficacy and safety in patients with osteoarthritis (OA), including subgroup analyses of at-risk patients with diabetes, severe OA symptoms, and those aged ≥65 years.

Patients and methods: Data from phase III placebo-controlled clinical trials of patients with moderate-to-severe OA of the knee or hip were pooled to evaluate tanezumab efficacy (four trials) and safety (nine trials). Patients received intravenous tanezumab, tanezumab plus an oral NSAID (naproxen, celecoxib, or diclofenac), active comparator (naproxen, celecoxib, diclofenac, or oxycodone), or placebo. Efficacy assessments included change from baseline to week 16 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores, Patient's Global Assessment (PGA) of OA, and percentage of patients with ≥30%, ≥50%, ≥70%, and ≥90% improvement in WOMAC pain. Safety assessments included adverse event (AE) documentation and physical and neurologic examinations.

Results: Tanezumab significantly improved all efficacy end points in the overall population. Efficacy in at-risk patient subgroups was similar to the overall population. Incidence of AEs was highest in the tanezumab plus NSAID group and lowest in the placebo group. Incidence of AEs in the tanezumab monotherapy and active comparator groups was similar. Overall incidence of AEs was similar across subgroups. AEs of abnormal peripheral sensation were more frequently reported in tanezumab-treated patients compared with placebo or active comparator. Patients receiving active comparator had a slightly higher incidence of AEs suggestive of postganglionic sympathetic dysfunction.

Conclusion: Tanezumab consistently provided significant improvement of pain, physical function, and PGA in individuals with OA, including patients with diabetes, severe OA symptoms, or aged ≥65 years. No increased safety risk was observed in at-risk patient subgroups.

Trial registration: NCT00733902, NCT00744471, NCT00830063, NCT00863304, NCT00809354, NCT00864097, NCT00863772, NCT01089725, NCT00985621.

Keywords: efficacy; nerve growth factor; osteoarthritis; safety; tanezumab.

Conflict of interest statement

Disclosure LT, HN, MTB, and CRW are employees of and hold stock and/or stock options in Pfizer Inc; AEB is currently a speaker and serves on advisory boards for Pfizer Inc; TJS received funding for the ongoing clinical research studies from Pfizer Inc and Regeneron; the authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Least squares mean change in WOMAC pain (A), WOMAC physical function (B), and Patient’s Global Assessment (C) from baseline to week 16 for the overall population. Notes: *P≤0.05; **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; LS, least squares; PGA, Patient’s Global Assessment; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 2
Figure 2
Least squares mean change in WOMAC pain from baseline to week 16 for the subgroup analyses. Notes: *P≤0.05; **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; LS, least squares; OA, osteoarthritis; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 3
Figure 3
Least squares mean change in WOMAC physical function from baseline to week 16 for the subgroup analyses. Notes: *P≤0.05; **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; LS, least squares; OA, osteoarthritis; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 4
Figure 4
Least squares mean change in PGA from baseline to week 16 for the subgroup analyses. Notes: *P≤0.05; **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; LS, least squares; OA, osteoarthritis; PGA, Patient’s Global Assessment; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 5
Figure 5
Percentage of patients with ≥30%, ≥50%, ≥70%, and ≥90% improvement on the WOMAC pain subscale at week 16 (overall group). Notes: **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 6
Figure 6
Percentage of patients with ≥30%, ≥50%, ≥70%, and ≥90% improvement on the WOMAC pain subscale at week 16 in the subgroups. Notes: *P≤0.05; **P≤0.01; ***P≤0.001 vs placebo. ^P≤0.05; ^^P≤0.01; ^^^P≤0.001 vs naproxen. Abbreviations: BID, twice daily; OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Similar articles

See all similar articles

Cited by 1 article

References

    1. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363–388. - PubMed
    1. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465–474. - PubMed
    1. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162. - PubMed
    1. Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3(1):e000133. - PMC - PubMed
    1. Sowers JR, White WB, Pitt B, et al. Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161–168. - PubMed

Associated data

Feedback